Tbio RNPS1 RNA-binding protein with serine-rich domain 1

Protein Summary

Description

Part of pre- and post-splicing multiprotein mRNP complexes. Auxiliary component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junction on mRNAs. The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. Component of the ASAP and PSAP complexes which bind RNA in a sequence-independent manner and are proposed to be recruited to the EJC prior to or during the splicing process and to regulate specific excision of introns in specific transcription subsets. The ASAP complex can inhibit RNA processing during in vitro splicing reactions. The ASAP complex promotes apoptosis and is disassembled after induction of apoptosis. Enhances the formation of the ATP-dependent A complex of the spliceosome. Involved in both constitutive splicing and, in association with SRP54 and TRA2B/SFRS10, in distinctive modulation of alternative splicing in a substrate-dependent manner. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the activity is different from the established EJC assembly and function. Participates in mRNA 3'-end cleavage. Involved in UPF2-dependent nonsense-mediated decay (NMD) of mRNAs containing premature stop codons. Also mediates increase of mRNA abundance and translational efficiency. Binds spliced mRNA 20-25 nt upstream of exon-exon junctions. This gene encodes a protein that is part of a post-splicing multiprotein complex involved in both mRNA nuclear export and mRNA surveillance. mRNA surveillance detects exported mRNAs with truncated open reading frames and initiates nonsense-mediated mRNA decay (NMD). When translation ends upstream from the last exon-exon junction, this triggers NMD to degrade mRNAs containing premature stop codons. This protein binds to the mRNA and remains bound after nuclear export, acting as a nucleocytoplasmic shuttling protein. This protein contains many serine residues. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]

Uniprot Accession IDs

• Q15287
• A8K1P0
• B4DDU8
• B4DZU7
• B7ZA17
• O75308
• Q32P25
• Q8WY42
• Q9NYG3

Gene Name

• RNPS1

Ensembl ID

• ENST00000301730
• ENSP00000301730
• ENSG00000205937
• ENST00000320225
• ENSP00000315859
• ENST00000397086
• ENSP00000380275
• ENST00000565678
• ENSP00000457723
• ENST00000566458
• ENSP00000456352
• ENST00000568631
• ENSP00000457820

Symbol

• LDC2
• E5.1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
co-expressed gene	0.97
kinase perturbation	0.96
histone modification site profile	0.85
interacting protein	0.85
transcription factor binding site profile	0.84

Protein Classes

PANTHER Classes

Protein / Nucleic Acid Binding / Rna Binding Protein / Mrna Processing Factor / Mrna Splicing Factor / Rna-binding Protein With Serine-rich Domain 1

DTO Classes

Protein / Nucleic Acid Binding / Rna Binding Protein / Mrna Processing Factor / Mrna Splicing Factor / Rna-binding Protein With Serine-rich Domain 1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 40.7   (req: < 5)

Gene RIFs: 10   (req: <= 3)

Antibodies: 69   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 40.7   (req: >= 5)

Gene RIFs: 10   (req: > 3)

Antibodies: 69   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 12

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0